ScholarIQanswers from OpenAlex
Dana-Farber Cancer Institute
InstitutionResearch output, impact & collaborations
Dana-Farber Cancer Institute is a institution indexed in ScholarIQ from OpenAlex.
What is known about Dana-Farber Cancer Institute?
ScholarIQrecord summary
Dana-Farber Cancer Institute is a research organisation in Boston, US. OpenAlex records 89,208 works and 27,485,770 citations for it. 14,518 researchers list it as their most recent affiliation.
How many works does Dana-Farber Cancer Institute have?
ScholarIQindexed works
Dana-Farber Cancer Institute has 89,208 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Dana-Farber Cancer Institute have?
ScholarIQcitation count
Dana-Farber Cancer Institute has 27,485,770 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at Dana-Farber Cancer Institute?
ScholarIQresearcher count
Dana-Farber Cancer Institute has 14,518 researchers in the ScholarIQ index.
What is the average h-index at Dana-Farber Cancer Institute?
ScholarIQavg h-index
Dana-Farber Cancer Institute has an average h-index of 70.7 in OpenAlex.
What is the ROR of Dana-Farber Cancer Institute?
ScholarIQror
The ROR for Dana-Farber Cancer Institute is on the source record.
What is the OpenAlex record for Dana-Farber Cancer Institute?
ScholarIQopenalex
The OpenAlex for Dana-Farber Cancer Institute is on the source record.
Who are the most-cited researchers behind Dana-Farber Cancer Institute?
ScholarIQtop researchers by citations
What are the most-cited papers on Dana-Farber Cancer Institute?
ScholarIQmost cited works
Bioconductor: open software development for computational biology and bioinformatics
Robert Gentleman, Vincent J. Carey, Douglas M. Bates, Ben Bolstad, Marcel Dettling, Sandrine Dudoit, Byron Ellis, Laurent Gautier, Yongchao Ge, Jeff Gentry, Kurt Hornik, Torsten Hothorn, Wolfgang Huber, Stefano M. Iacus, Rafael A. Irizarry, Friedrich Leisch, Cheng Li, Martin Maechler, Anthony Rossini, Günther Sawitzki, Colin A. Smith, Gordon K. Smyth, Luke Tierney, Jean Yang, Jianhua Zhang
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
J. Guillermo Paez, Pasi A. Jänne, Jeffrey C. Lee, Sean Tracy, Heidi Greulich, Stacey Gabriel, Paula Herman, Frederic J. Kaye, Neal I. Lindeman, Titus J. Boggon, Katsuhiko Naoki, Hidefumi Sasaki, Yoshitaka Fujii, Michael J. Eck, William R. Sellers, Bruce E. Johnson, Matthew Meyerson
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Alan Sandler, Robert J. Gray, Michael C. Perry, Julie R. Brahmer, Joan H. Schiller, Afshin Dowlati, Rogério Lilenbaum, David H. Johnson
A Draft Sequence of the Neandertal Genome
Richard E. Green, Johannes Krause, Adrian W. Briggs, Tomislav Maričić, Udo Stenzel, Martin Kircher, Nick Patterson, Heng Li, Weiwei Zhai, Markus Hsi-Yang Fritz, Nancy F. Hansen, Éric Durand, Anna‐Sapfo Malaspinas, Jeffrey D. Jensen, Tomàs Marquès‐Bonet, Can Alkan, Kay Prüfer, Matthias Meyer, Hernán A. Burbano, Jeffrey M. Good, Rigo Schultz, Ayinuer Aximu‐Petri, Anne Butthof, Barbara Höber, Barbara Höffner, Madlen Siegemund, Antje Weihmann, Chad Nusbaum, Eric S. Lander, Carsten Russ, Nathaniel Novod, Jason P. Affourtit, Michael Egholm, Christine Verna, Pavao Rudan, Dejana Brajković, Željko Kućan, Ivan Gušić, Vladimir B. Doronichev, Liubov V. Golovanova, Carles Lalueza‐Fox, Marco de la Rasilla Vives, Javier Fortea, Antonio Rosas, Ralf W. Schmitz, Philip L. Johnson, Evan E. Eichler, Daniel Falush, Ewan Birney, James C. Mullikin, Montgomery Slatkin, Rasmus Nielsen, Janet Kelso, Michael Lachmann, David Reich, Svante Pääbo
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Jeffrey A. Engelman, Kreshnik Zejnullahu, Tetsuya Mitsudomi, Youngchul Song, Courtney Hyland, Joon Oh Park, Neal I. Lindeman, Christopher-Michael Gale, Xiao‐Jun Zhao, James G. Christensen, Takayuki Kosaka, Alison J. Holmes, Andrew M. Rogers, Federico Cappuzzo, Tony Mok, Charles Lee, Bruce E. Johnson, Lewis C. Cantley, Pasi A. Jänne
Who collaborates most closely around Dana-Farber Cancer Institute?
ScholarIQco-authorship network
United States
100%
How much of the research on Dana-Farber Cancer Institute is open access?
ScholarIQopen access share
75%OPEN ACCESS